Abstract
The authors, using novel immunoassays, investigated CSF α-synuclein oligomer levels in patients with Parkinson disease (PD) and controls. Since the levels of α-synuclein oligomers in CSF were higher in patients with PD compared to controls, these levels may be useful biomarkers for early detection and diagnosis of PD. See p. 1766; Editorial, p. 1760 This study followed 89 patients with Parkinson disease (PD) who had either normal sleep without hallucinations, sleep fragmentation only, vivid dreams/nightmares, hallucinations with insight, or hallucinations without insight. The increasing prevalence and progressive severity …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
